Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna golimumab coverage & prior auth | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0790

    Golimumab (Simponi and Simponi Aria) coverage

    Customize your policy alerts

    Sign up for Aetna Policy 0790 alerts

    Get alerted when Policy 0790 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and utilization management criteria for intravenous (Simponi Aria) and subcutaneous (Simponi) golimumab for Aetna commercial medical plans, including prescriber requirements, indications, continuation criteria, dosing notes, and precertification/site-of-care rules.

    Policy Summary
    PayerAetna
    PolicyGolimumab (Simponi and Simponi Aria) coverage
    Policy CodePolicy 0790
    Change TypeNo material change
    Effective DateJul 10, 2009
    Last ReviewFeb 20, 2024
    Next Review DateAug 22, 2024
    Key ActionPrecertification is required for intravenous golimumab (Simponi Aria); use HCPCS J1602 and document indication, dosing, and prior methotrexate therapy when requesting authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Formulations
    MultipleIndications
    RequiredPrecertification
    6 monthsTB screening window
    Not allowedConcomitant biologics
    02/20/2024Last review

    Coverage and Medical Necessity Criteria

    Coverage criteria not included in this excerpt

    The following coverage-related content items were present in the source but not included in the preceding excerpt. They are consolidated here to ensure completeness and to inform coverage decisions, coding, and clinical context.

    Appendices: Appendix C lists brands of targeted immune modulators and their FDA-labeled indications; notable entries include Simponi (golimumab) — indications: ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Simponi Aria (intravenous golimumab) — indications: ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis. (See Appendix C.)
    References and Evidence Base: The policy is supported by multiple clinical trials, guidance documents, and regulatory materials including but not limited to the pivotal randomized controlled trials (GO-FURTHER, GO-VIBRANT, GO-FORWARD, GO-RAISE, GO-VIVA), prescribing information for Simponi and Simponi Aria, and society guidelines (ACR, EULAR, ASAS, AGA, GRAPPA). Key references: Janssen prescribing information (Simponi, Simponi Aria), pivotal trial publications (Inman 2008; Sandborn 2014; Janssen 2017 press releases), and multiple guideline publications listed in the references section.
    Coding and Billing Notes: The CPT/HCPCS/ICD-10 coding guidance in the source includes covered ICD-10 codes when selection criteria are met for IV and subcutaneous formulations (e.g., M05.-/M06.- for rheumatoid arthritis, L40.50-L40.59 for arthropathic psoriasis, M45.- for ankylosing spondylitis, K51.- for ulcerative colitis). Codes explicitly listed as not covered for certain indications include Crohn's disease (K50.-), ocular inflammatory disorders (H20.- H21.-), asthma (J45.-), sarcoidosis of lung (D86.0) for the subcutaneous formulation, among others. Specific HCPCS/J-codes and biosimilar Q-codes referenced in the source were included for cross-reference and billing context.
    Policy Summary
    PayerAetna
    PolicyGolimumab (Simponi and Simponi Aria) coverage
    Policy CodePolicy 0790
    Change TypeNo material change
    Effective DateJul 10, 2009
    Last ReviewFeb 20, 2024
    Next Review DateAug 22, 2024
    Key ActionPrecertification is required for intravenous golimumab (Simponi Aria); use HCPCS J1602 and document indication, dosing, and prior methotrexate therapy when requesting authorization.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes and Code ListsPrecertification, Documentation, and Provider RequirementsBackground and RationaleDefinitions and Key TermsPolicy Revision History
    Experimental / Investigational and Exclusions (summary): The source explicitly states that concomitant use of golimumab with any other biologic or targeted synthetic agent for the same indication is considered experimental and investigational. Intravenous golimumab is considered experimental/investigational for several indications (e.g., Behcet's disease, Crohn's disease, non-infectious uveitis, panuveitis, posterior uveitis, scleritis). Subcutaneous golimumab is considered experimental/investigational for other indications including asthma, Behcet's, Crohn's disease, non-infectious uveitis, panuveitis, posterior uveitis, sarcoidosis, and scleritis.
    Safety and Negative Trial Findings: The source includes evidence of lack of favorable risk–benefit in some indications — e.g., golimumab did not demonstrate benefit and had unfavorable outcomes in severe persistent asthma trials (Wenzel 2009), and did not demonstrate effectiveness in pulmonary sarcoidosis (Judson 2014). These findings are cited as rationale for noncoverage/experimental determinations in those indications.
    Pediatric and Label Extensions: The source documents FDA approval (2020) of Simponi Aria for patients 2 years and older for active polyarticular juvenile idiopathic arthritis (pJIA) and an extension of the PsA indication for pediatric patients; GO-VIVA trial (NCT02277444) supported the pJIA approval. Coverage criteria for pediatric age groups should reflect these approvals where applicable.
    Operational/Clinical Context Notes: Trial designs, concomitant medication allowances, and key efficacy endpoints used in trials are summarized in the background (e.g., ACR20/50/70, ASAS20/40, PASI75, Mayo score, HAQ-DI). These endpoints informed the policy's trial-based efficacy measures and continuation criteria.
    Cross-policy and Guideline References: The source references multiple guideline bodies and technology assessments (ACR, EULAR, GRAPPA, NICE, CADTH, AGA, NCCN compendium) that were used to inform policy criteria and the therapeutic role of golimumab across indications.
    Document History and Review Dates: Policy effective date and maintenance metadata from the source include Effective: 07/10/2009, Last Review: 02/20/2024, Next Review: 08/22/2024. These dates provide versioning context for applicability of referenced evidence and coding.
    Footnotes and TB Testing Requirement: The source reiterates the requirement for documented negative tuberculosis (TB) screening (e.g., PPD, IGRA, or chest x-ray) within 6 months of initiating therapy for persons naive to biologic or targeted synthetic agents associated with increased TB risk; this is an operational requirement across formulations and indications.

    Billing Codes and Code Lists

    Other related CPT/HCPCS codes and specific golimumab HCPCSmixed
    71045-71048Radiologic examination, chest
    85651Sedimentation rate, erythrocyte; non-automated
    85652Sedimentation rate, erythrocyte; automated
    86140C-reactive protein
    86141C-reactive protein; high sensitivity (hsCRP)
    86200Cyclic citrullinated peptide (CCP), antibody
    86430Rheumatoid factor; qualitative
    86431Rheumatoid factor; quantitative
    86480Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
    86481Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon - producing T cells in cell suspension
    1–10 of 21
    1/3
    Related CPT/HCPCS lab and administration codesmixed
    71045-71048Radiologic examination, chest
    85651Sedimentation rate, erythrocyte; non-automated
    85652Sedimentation rate, erythrocyte; automated
    86140C-reactive protein
    86141C-reactive protein; high sensitivity (hsCRP)
    86200Cyclic citrullinated peptide (CCP), antibody
    86430Rheumatoid factor; qualitative
    86431Rheumatoid factor; quantitative
    86480Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
    86481Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon - producing T cells in cell suspension
    1–10 of 17
    1/2
    Other HCPCS/J-codes related to the CPBHCPCS
    J0129Injection, abatacept, 10 mg
    J0135Injection, adalimumab, 20 mg
    J0717Injection, certolizumab pegol, 1 mg
    J1438Injection, etanercept, 25 mg
    J1745Injection infliximab, 10 mg
    J3262Injection, tocilizumab, 1 mg
    J8610Methotrexate, oral, 2.5 mg
    J9250Methotrexate sodium, 5 mg
    J9312Injection, rituximab, 10 mg
    Q5109Injection, infliximab-qbtx, biosimilar (ixifi), 10 mg
    1–10 of 13
    1/2
    ICD-10 codes (covered if selection criteria met / not covered lists)ICD-10
    L40.50-L40.59Arthropathic psoriasis
    M05.00-M06.9Rheumatoid arthritis
    M08.00-M08.99Juvenile idiopathic arthritis
    M13.80-M13.89Other specified arthritis [severe immunotherapy-related arthritis]
    M45.0-M45.ABAnkylosing spondylitis
    T45.1X5A-T45.1X5SAdverse effect of antineoplastic and immunosuppressive drugs [immune checkpoint inhibitor toxicity]
    K51.00-K51.919Ulcerative colitis
    K50.00-K50.919Crohn's disease (listed as not covered for CPB indications)
    H20.00-H21.29Disorders of iris and ciliary body [ocular inflammatory disorders] (listed as not covered for CPB indications)
    Product packaging/HCPCS referenceNDC
    50mg/4mlSimponi Aria supplied vial strength as 50mg/4ml (documented vial presentation)
    Product strengths and dosing describedmixed
    50mg/4ml vialSimponi Aria supplied as individually boxed single-use vials (50 mg/4 mL) for IV injection
    2 mg/kg IVSimponi Aria dosing regimen for RA: 2 mg/kg IV at weeks 0 and 4 then every 8 weeks
    80 mg/m2 IVSimponi Aria dosing used in GO-VIVA for pJIA: 80 mg/m2 at Week 0, 4, then every 8 weeks through Week 52
    No explicit codes in this excerptmixed
    No codes listed
    Methotrexate adequate dosing — key thresholds
    Methotrexate adequate dosing>= 15 mg/week (defined as adequate dosing for methotrexate trial prior to golimumab)
    Methotrexate trial durationAt least 3 months of methotrexate prior to considering golimumab (when applicable)
    Exception documentationClinical reasons to avoid methotrexate (see Appendix A) may justify bypassing the MTX requirement
    BASDAI inclusion threshold
    BASDAI inclusion threshold>= 4 (Bath Ankylosing Spondylitis Disease Activity Index used as enrollment criterion in AS trials)
    Trial contextUsed with other criteria (e.g., VAS back pain >=4 and hsCRP thresholds) in AS pivotal trials
    PopulationAdult patients with active AS per modified New York criteria in trial enrollment
    Back pain VAS threshold (AS trials)
    Back pain VAS threshold>= 4/10 (Visual analogue scale for total back pain used as enrollment criterion in AS trials)
    Scale interpretationVAS measured on 0–10 cm (0–100 mm) scale; threshold corresponds to moderate-to-severe pain
    Trial pairingApplied alongside BASDAI >=4 and hsCRP >=0.3 mg/dL in GO-ALIVE AS trial enrollment
    Clinical eligibility thresholds in GO (golimumab IV) trials
    Psoriatic arthritis (GO‑VIBRANT) enrollment thresholds>= 5 swollen joints AND >= 5 tender joints AND CRP >= 0.6 mg/dL
    Ankylosing spondylitis (GO‑ALIVE) enrollment thresholdsBASDAI >= 4 AND VAS back pain >= 4 AND hsCRP >= 0.3 mg/dL
    Population contextBiologic‑naive adults enrolled in pivotal IV trials with these activity requirements
    Trial entry tender/swollen joint minimum (RA IV trial)
    Trial joint-count minimum (RA GO‑FURTHER)>= 6 tender joints and >= 6 swollen joints required at screening and baseline in the IV RA pivotal trial
    Background MTX requirementPatients had been receiving background methotrexate for at least 3 months in GO‑FURTHER
    Elevated inflammation requirementTrial required elevated CRP at screening for enrollment

    Precertification, Documentation, and Provider Requirements

    Prior Authorization

    Precertification Required for IV Golimumab

    Precertification of intravenous golimumab (Simponi Aria) is required for all Aetna participating providers and applicable plan designs. Failure to precertify may result in denial of coverage. For precertification call (866) 752-7021 or fax (888) 267-3277. See Specialty Pharmacy Precertification forms for Statement of Medical Necessity (SMN).

    • Precertification phone: (866) 752-7021; fax: (888) 267-3277
    • Simponi Aria (IV) requires precertification
    • Site of Care UM policy may apply for infusions
    Documentation Required

    TB Testing and Prior Therapy Documentation

    Document a negative tuberculosis (TB) test (PPD, IGRA, or chest x-ray) within 6 months of initiating golimumab for biologic/targeted-synthetic–naive persons. Record prior therapies and dates when submitting authorization requests.

    • Acceptable TB tests: PPD, IGRA, or chest x-ray within 6 months
    • Document prior conventional and biologic/targeted-synthetic therapies and dates
    Documentation Required

    Required Clinical Documentation for Prior Authorization

    Prior authorization requests must include required clinical documentation: diagnosis, prior DMARD use (including methotrexate) with dosing and duration, biomarker/test results where applicable (RF, anti-CCP, CRP/ESR), and rationale if methotrexate or leflunomide are not used.

    • Document diagnosis and relevant ICD-10 code
    • Document biomarker results: RF, anti-CCP, CRP and/or ESR
    • If bypassing MTX/leflunomide, provide clinical reason per Appendix A
    Prior Authorization

    Prior Authorization: Evidence of Prior Methotrexate and Dosing

    Prior authorization must document prior methotrexate therapy and dosing where required by indication (examples: RA — at least a 3-month trial with MTX titrated to ≥15 mg/week; pJIA — at least 2 months of MTX). If member previously received biologic or targeted synthetic drugs, document specifics.

    • RA: inadequate response to ≥3 months of MTX at adequate dose (≥15 mg/week) or intolerance/contraindication
    • pJIA: documented MTX for at least 2 months in the trial (GO-VIVA context)
    • Document prior biologic/targeted-synthetic exposure when relevant
    Step Therapy

    Therapy Trial Requirements

    Therapy trial requirements apply across multiple indications: members must have trialed and had an inadequate response to or intolerance of specified conventional therapies (e.g., MTX, leflunomide, sulfasalazine, NSAIDs) before approval, unless a clinical reason to omit is documented.

    • Document trials of conventional synthetic DMARDs (MTX, leflunomide, sulfasalazine) with dose and duration
    • NSAID trials required for AS/nr-axSpA (typically ≥2 NSAIDs unless contraindicated)
    Step Therapy

    Therapy Sequencing for Ulcerative Colitis

    For ulcerative colitis (UC), sequencing rules require prior failure, intolerance, or corticosteroid dependence after oral aminosalicylates, oral corticosteroids, azathioprine, or 6‑mercaptopurine as described in FDA indication language. Document prior UC therapies and steroid dependence or inadequate response.

    • UC dosing/induction for subcutaneous golimumab: 200 mg at Week 0, 100 mg at Week 2, then 100 mg every 4 weeks
    • Document prior use/failure of aminosalicylates, corticosteroids, azathioprine, or 6‑MP
    Billing Rule

    Coding and Claim Documentation

    Coding and claim submission must use appropriate HCPCS/J-codes and CPT codes. Use HCPCS J1602 for intravenous golimumab (Simponi Aria) — Injection, golimumab, 1 mg (IV). Include infusion administration CPT/HCPCS (e.g., 96365-96368) and relevant testing codes (e.g., TB test, CRP, RF) on claims as applicable. Subcutaneous Simponi has no specific HCPCS J‑code.

    • HCPCS J1602 = Injection, golimumab, 1 mg (Simponi Aria IV)
    • Include infusion administration codes: CPT 96365-96368 as applicable
    • Include diagnostic/testing codes: 86580/86480/86140/86200 etc. when documented
    Documentation Required

    Infusion Dosing Documentation

    Infusion dosing and schedule for Simponi Aria must be documented: weight-based 2 mg/kg IV over 30 minutes at weeks 0 and 4, then every 8 weeks for adults (RA/PsA/AS). For pJIA, document BSA-based dosing of 80 mg/m2 IV at weeks 0 and 4, then every 8 weeks. Document concurrent methotrexate when required and any concomitant medications.

    • Adult IV dosing: 2 mg/kg IV over 30 minutes at weeks 0, 4, then every 8 weeks
    • pJIA IV dosing: 80 mg/m2 IV over 30 minutes at weeks 0, 4, then every 8 weeks
    • Document concomitant methotrexate unless clinical reason to avoid
    Note

    Trial Population Considerations

    Trial population considerations: note key trial exclusions or contexts that affect interpretation of prior therapy — e.g., some PsA trials excluded prior TNF-blocker exposure; GO-FURTHER RA trial required background methotrexate for ≥3 months. Document how the member's prior therapy and trial context align with clinical evidence.

    • PsA pivotal trial excluded prior biologic TNF-blocker exposure — document prior biologic history
    • GO-FURTHER RA trial required background MTX for ≥3 months — relevant when assessing evidence
    Denial Risk

    Coverage-Code Matching

    Coverage-code mismatches may lead to denial. Ensure the ICD-10 diagnosis code submitted matches a covered indication for the specific formulation (IV vs SC). For example, some ICD-10 codes are covered for Simponi Aria but not for Simponi and vice versa; use the ICD-10 lists provided and verify selection criteria are met.

    • Verify ICD-10 code matches covered indication and formulation (IV vs SC)
    • ICD-10 codes not covered for CPB-listed indications may trigger denial (e.g., Crohn's disease is not covered)
    Note

    Administrative / Prior Authorization Notes

    No additional prior authorization details are specified in this excerpt beyond the above requirements; administrative metadata and policy history are available in the document footer. For plan‑specific variations, confirm with the member's benefit plan.

    • Policy effective date: 2009-07-10; last review 02/20/2024
    • Plan-specific rules may vary — verify member benefits

    Background and Rationale

    Background: golimumab is a human monoclonal antibody that binds tumor necrosis factor‑alpha and inhibits its interaction with TNF receptors. It is available as Simponi (subcutaneous) and Simponi Aria (intravenous), with FDA‑labeled indications summarized in the policy appendix.

    Definitions and Key Terms

    Precertification — prior authorization requirements
    Precertification required for IV golimumabPrecertification (prior authorization) is required for intravenous golimumab (Simponi Aria) for participating providers and applicable plan designs
    Use HCPCS J-codeSimponi Aria is billed per mg using HCPCS code J1602 (Injection, golimumab, 1 mg) for IV formulation
    Denial riskFailure to precertify IV golimumab for applicable plans may lead to denial of coverage
    Experimental and investigational — definition and examples
    Definition: experimental and investigationalUse judged by Aetna as not established because effectiveness has not been demonstrated
    Example: concomitant biologic useConcomitant use of golimumab with any other biologic or targeted synthetic drug for the same indication is considered experimental/investigational
    Example: off‑label indicationsIV golimumab and SC golimumab are considered experimental/investigational for various off‑label indications (e.g., Behcet's disease, Crohn's disease, non‑infectious uveitis, sarcoidosis, scleritis, asthma) as listed
    Golimumab — definition and mechanism of action
    Drug class and mechanismGolimumab is a human monoclonal antibody that inhibits TNF‑alpha by binding and blocking its interaction with TNF receptors
    FormulationsAvailable as Simponi (subcutaneous) and Simponi Aria (intravenous)
    Clinical roleTNF‑alpha inhibition reduces articular inflammation implicated in RA, PsA, and AS
    Axial spondyloarthritis (axSpA) — definition
    Definition: axial spondyloarthritis (axSpA)A group of spondyloarthritis diseases affecting the spine, including ankylosing spondylitis (radiographic) and nonradiographic axial spondyloarthritis (nr‑axSpA); diagnosis requires a combination of clinical and imaging features
    Typical onsetSymptoms typically begin before age 45 and include chronic back pain and inflammatory features
    Diagnostic approachNo single finding is diagnostic; combination of features and exclusion of other causes is required
    ACR20 — definition and trial use
    ACR20 definitionAmerican College of Rheumatology 20% improvement criteria (ACR20) — a primary efficacy endpoint used in RA and PsA trials indicating >=20% improvement in defined measures
    Trial useACR20 at week 14 was the primary endpoint in multiple golimumab pivotal trials (e.g., GO‑VIBRANT, GO‑FURTHER)
    Related endpointsHigher thresholds (ACR50/70) and radiographic outcomes (vdH‑S) were also reported in trials
    Mayo score — UC disease activity index
    Mayo score definitionMayo score — a composite index used to assess ulcerative colitis disease activity (trial ranges referenced, e.g., 6 to 12)
    Trial contextUsed to assess clinical response and remission in UC phase 2/3 golimumab trials
    ComponentsIncludes stool frequency, rectal bleeding, endoscopic findings, and physician global assessment (composite) as applied in trials
    vdH‑S score — radiographic score definition
    vdH‑S score definitionvan der Heijde‑Sharp (vdH‑S) radiographic score — measures joint erosion and joint space narrowing; higher scores indicate greater structural damage
    Trial useUsed to assess radiographic progression in GO‑FURTHER RA trial (hands and feet radiographs scored at baseline, week 24, and week 52)
    InterpretationSmaller change from baseline indicates inhibition of structural damage (e.g., golimumab group showed minimal progression vs placebo)
    Simponi and Simponi Aria — brand names and formulation distinction
    Brand and formulation distinctionSimponi = subcutaneous golimumab; Simponi Aria = intravenous golimumab (distinct formulations with different FDA‑labeled indications)
    FDA‑labeled indications (examples)Simponi: ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis; Simponi Aria: ankylosing spondylitis, juvenile idiopathic arthritis, psoriatic arthritis, rheumatoid arthritis
    Packaging noteSimponi Aria supplied as 50 mg/4 mL single‑use vials (per product packaging references in the policy)

    Policy Revision History

    2024-02-20policy_reviewLatest

    Policy last reviewed; administrative metadata updated (last review and effective/next review dates shown).

    2009-07-10policy_effective

    Policy effective date (original effective date for the golimumab coverage policy).

    2017-10-20label_update

    FDA approvals announced for Simponi Aria for adult psoriatic arthritis and ankylosing spondylitis (manufacturer news release).

    2020-09-30label_update

    Simponi Aria approval extended to include polyarticular juvenile idiopathic arthritis in patients 2 years and older (manufacturer press release).